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To the Editor:
Drs. Wilkes and Navickis are incorrect that it is the institutional
policy of our hospital to encourage the use of hetastarch over
albumin. The clinical algorithm our division prepared on this
topic was revised in light of the bleeding risk we reported in our
publication.1 We do not disagree with the contention that
hetastarch probably increases the risk of postoperative bleeding;
this was, after all, the main conclusion of our article. Our main
point was not to criticize their metaanalysis on this subject, nor
their other work supported by the manufacturers of albumin
products; the methodologic concerns we cited were primarily
raised by others.2,3 However, we do not agree with their conclu-
sion that it is time to routinely replace hetastarch with plasma
protein products. Clinical policy about such an important matter
should be based on large, impeccably conducted randomized
controlled clinical trials that compare the relevant choices head-
to-head for safety and efficacy. That is particularly necessary in
this case because of the important countervailing risks that may
be associated with albumin use. A systematic review of random-
ized controlled trials published in the British Medical Journal by
the Cochrane Collaborative found increased mortality rates in
critically ill patients randomized to receive albumin.4 That review
was recently updated to include a total of 31 randomized
controlled trials; this more recent analysis reported a relative risk
for death of 1.52 (95% confidence interval, 1.17 to 1.99) in
patients randomized to receive albumin vs no albumin, or
albumin vs crystalloid. The authors of that report concluded that
albumin use would produce one extra death for every 20 critically
ill patients receiving albumin.5
As the experience with hormone replacement therapy amply
demonstrates,6 even carefully conducted epidemiologic studies
such as our own cannot exclude the possibility that patient
selection and other confounders might produce incorrect conclu-
sions about the efficacy or safety of commonly used medications.
Given the frequency of use of colloids and the importance of the
risks being considered, it is time for a randomized trial comparing
hetastarch with albumin to resolve these issues once and for all.
Studies of this kind have begun to appear in the literature.7 It is
a major failing of our current system for the evaluation of drugs
and biological agents that no mechanism exists to ensure that
such comparative studies are done promptly, thoroughly, and
even-handedly as a matter of routine policy.8
Jerry Avorn, MD
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Boston, MA
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Cardiogenic Shock
To the Editor:
We wish to clarify a few points in the data presented by Lim
and colleagues (November 2003).1 Eighteen patients presented
with acute myocardial infarction that developed into cardiogenic
shock (CS). No mention is made about the method of reperfusion
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or revascularization, information that is absolutely essential in
light of the findings of the Should We Emergently Revascularize
Occluded Coronaries for Cardiogenic Shock (SHOCK) trial.2 An
institutional protocol that uses intra-aortic balloon pumps
(IABPs) only in those patients with refractory CS, despite the use
of therapy with vasopressors, is not dispensing state-of-the art
care to patients with CS. While the benefit of therapy with
vasopressors on outcome in patients with CS is doubtful, a
survival benefit is evident in patients who are supported with an
IABP, and this is included in the current American College of
Cardiology/American Heart Association guidelines. Data from
the SHOCK trial and Registry demonstrated that the reversal of
systemic hypoperfusion following IABP therapy is associated with
improved 30-day survival, independent of early revascularization.3
Hochman also has proposed alterations to the current model
and has suggested expanding the paradigm in a recent review.4
Large myocardial infarctions that are complicated by CS may be
accompanied by a substantial inflammatory response with the
release of various mediators, including cytokines, leading to high
levels of nitric oxide and peroxynitrite with deleterious effects. A
nitric oxide synthase inhibitor will be utilized in the SHOCK-2
trial to test this hypothesis.
A recent concept introduced into the lexicon of shock termi-
nology is the cardiac power output. This parameter is calculated
by multiplying the mean arterial pressure by the cardiac output.
This parameter was found on multivariate analysis to be the
single hemodynamic factor associated with in-hospital mortality
among patients in the SHOCK Registry.5 It would be interesting
to know whether Lim and colleagues will confirm this finding in
their cohort of patients as they have data on the mean arterial
pressure and CO for each patient.
Francisco Jose´ Munoz, MD
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To the Editor:
We thank Drs. Munoz and Thomas for their comments on our
article. Indeed, the 18 patients with acute myocardial infarction
whose conditions evolved into cardiogenic shock were treated
according to the guidelines that were in effect at the time of the
study. The patients were admitted to the hospital in one of the
following three ways: (1) most were revascularized using percu-
taneous angioplasty unless coronary angiography disclosed dif-
fuse and/or distal lesions; (2) several patients developed shock a
few days after apparently successful thrombolysis; and (3) a small
groups of patients did not receive any revascularization interven-
tion due to the long delay between the onset of symptoms and
hospital admission. All patients were treated with antiplatelet
agents and heparin. Intra-aortic balloon counterpulsation was
used when possible, but this procedure was contraindicated in
some patients (in more nonsurvivors than survivors). These
factors do not invalidate our findings, as the aim of the study was
to describe the hemodynamic evolution of nonsurvivors, regard-
less of the results of any revascularization procedure they may
have received. Nine of the 23 nonsurviving patients developed
hyperdynamic shock, suggesting that pump failure was not the
primary cause of death. As both BP and cardiac output were
relatively preserved, cardiac power was not significantly de-
creased in these patients.
Finally, we agree, and indeed discussed briefly in our article,
that nitric oxide and peroxynitrite may be involved in this process.
It will be interesting to see the results of the SHOCK-2 trial.
Daniel De Backer, MD, PhD
Noelle Lim, MD
Jean-Louis Vincent, MD, PhD, FCCP
Free University of Brussels
Brussels, Belgium
Reproduction of this article is prohibited without written permis-
sion from the American College of Chest Physicians (e-mail:
permissions@chestnet.org).
Correspondence to: D. De Backer, MD, PhD, Department of
Intensive Care, Erasme University Hospital, Free University of
Brussels, 808 Lennik Rd, Brussels B-1070, Belgium; e-mail
ddebacke@ulb.ac.be
P Wave in Pulmonary Impairment
To the Editor:
We read with great interest the article by Asad et al in CHEST
(August 2003)1 on acute right atrial strain, and P-wave amplitude
and axis in the treatment of obstructive airways disease in patients
experiencing exacerbation. Their key message was the rapid
reversal of characteristic ECG changes with treatment from the
emergency department presentation to hospital ward admission.
Similarly, in 1973, Carilli et al2 demonstrated in a retrospective
study the predictive value of P-wave amplitude and axis in
estimating the severity of nonasthmatic airway obstructive disease
in the quiescent state. A good correlation of P-wave amplitude
and axis with FEV1/FVC and residual volume/total lung capacity
was seen, also demonstrating a continuum in regression equa-
tions. We agree with Yue et al,3 in their accompanying editorial,
that the study was well-designed but lacking in clinical and
functional data. Patients with clinical phenotypes of diffuse
obstructive airways disease (ie, chronic bronchitis/bronchiolitis,
emphysema and bronchial asthma) are a clinically and patho-
physiologically heterogeneous population. These various pheno-
types most often coexist, and the proportion of each is difficult to
quantitate clinically by pulmonary function testing and chest-
imaging techniques.
The variability of airways obstruction is a defining criteria
for the asthmatic type. Although these data are lacking in the
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